An educational initiative for the clinical community.

Radioligand therapy is one of the fastest-evolving areas in oncology. As alpha-emitting radiopharmaceuticals enter late-stage development, the clinical community needs accessible, rigorous education on the underlying science, the multidisciplinary care model, and the practical considerations for patient identification and treatment.

The Alpha Institute is a place to engage with that material — through webinars, downloadable resources, and structured content that meets clinicians where they are in their learning journey.

RayzeBio, a Bristol Myers Squibb company, is focused on the discovery and development of precision radiopharmaceutical therapies, with an innovation-leading position in actinium-based programs across solid tumors.

This site is independent of promotional materials for any approved product. Investigational pipeline information is shared for educational purposes and is not intended to promote unapproved uses.